Perfusion-Phase [(18)F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration

We aimed to test if early, perfusion phase tau-PET imaging with [(18)F]THK5351 might substitute for [(18)F]FDG PET information on neurodegeneration, as has been previously shown for amyloid-tracers. A patient with cognitive impairment and positive amyloid-PET was examined by [(18)F]THK5351 tau-PET a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brendel, Matthias, Wagner, Leonie, Levin, Johannes, Zach, Christian, Lindner, Simon, Bartenstein, Peter, Okamura, Nobuyuki, Rominger, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159627/
https://www.ncbi.nlm.nih.gov/pubmed/30480233
http://dx.doi.org/10.3233/ADR-170023
Descripción
Sumario:We aimed to test if early, perfusion phase tau-PET imaging with [(18)F]THK5351 might substitute for [(18)F]FDG PET information on neurodegeneration, as has been previously shown for amyloid-tracers. A patient with cognitive impairment and positive amyloid-PET was examined by [(18)F]THK5351 tau-PET and [(18)F]FDG PET. The pattern of early phase of [(18)F]THK5351 uptake was compared to [(18)F]FDG visually and by the dice similarity coefficient. Visual inspection of axial slices and stereotactic-surface projection indicated a striking agreement between combined 0–2 min p.i. perfusion images of [(18)F]THK5351 and standard [(18)F]FDG 30–60 min p.i. A two-phase protocol of [(18)F]THK5351 PET might give information on neurodegeneration and tau pathology in a single session.

Ejemplares similares